Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

603.P1.64 Oncogenes and Tumor Suppressors Poster I

Saturday, December 6, 2008: 5:30 PM-7:30 PM
Hall A (Moscone Center)
The Proto-Oncogene LRF Is Essential for Normal Mature B Cell Development and Germinal Center Formation

Nagisa Sakurai, PhD1*, Manami Maeda, MD, PhD1*, Sung-UK Lee, PhD1*, Julie Teruya-Feldstein, MD2* and Takahiro Maeda, MD, PhD1

1HSC and Leukemia Research, City of Hope National Medical Center, Duarte, CA
2Dept. of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY

Secondary Notch Activation Is Required for Efficient Oncogenesis and Tumor Growth in a Mouse Model of Ras-Initiated T-Cell Lymphoblastic Lymphoma

Mark Y Chiang, MD, PhD1*, M. Eden Childs, B.A.2*, Olga Shestova, Ph.D.2* and Warren S. Pear, MD, PhD2

1Medicine, Hematology/Oncology Division, University of Pennsylvania School of Medicine, Philadelphia, PA
2University of Pennsylvania, Philadelphia, PA

Functional Oncogene Identification in Patient Leukemia Samples

Akinori Yoda, Ph.D.1*, Martin Sattler, PhD2 and David M Weinstock, MD3

1Dana-Farber Cancer Institute, Boston, MA
2Dana-Farber Cancer Inst., Boston, MA
3Memorial Sloan-Kettering Cancer Center, New York, NY

Roles for the AML1/RUNX1 Point Mutation in the Pathogenesis of MDS/AML

Yusuke Satoh*, Itaru Matsumura, Hirokazu Tanaka*, Takafumi Yokota, Sachiko Ezoe*, Kenji Oritani* and Yuzuru Kanakura

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan

Alterations of the CxxC Domain Preclude Oncogenic Activation of Mixed Lineage Leukemia 2 (MLL2)

Robert K. Slany, PhD, Christian Bach*, Dorothee Mueller*, Sebastian Buhl* and Maria-Paz Garcia-Cuellar*

Dept. of Genetics, University Erlangen, Erlangen, Bavaria, Germany

Identification of Two 7q Genes Encoding Centrosomal Proteins as Myeloid Tumor-Suppressor Candidates

Hiroya Asou*, Yuko Ozaki*, Akiko Nagamachi*, Daisuke Aki*, Hirotaka Matsui* and Toshiya Inaba, MD

Department of Molecular Oncology, Research Institute for Radiation Biology & Medicine, Hiroshima University, Hiroshima, Japan

Specific Inhibition of Syk Is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin’s Lymphoma Cell Lines without Concomitant Inhibition of JAK

Greg Coffey, Ph.D.1*, Peng Luan, Ph.D.1*, Suzanne Delaney, Ph.D.1*, Anjali Pandey, Ph.D.2*, Zhaozhong Jia, Ph.D.2*, Qing Xu, Ph.D.2*, Shawn Bauer, Ph.D.2*, Yonghong Song, Ph.D.2*, Pamela B. Conley, Ph.D.1, David Phillips, Ph.D.1 and Uma Sinha, Ph.D.1

1Biology, Portola Pharmaceuticals Inc, S San Francisco, CA
2Chemistry, Portola Pharmaceuticals Inc, S San Francisco, CA

The Menin Tumor Suppressor Functions as a Molecular Adapter That Tethers LEDGF to MLL Proteins in Leukemogenesis

Akihiko Yokoyama, PhD1* and Michael Cleary, MD2

1Molecular Oncology Division, National Cancer Center Research Institute, Tokyo, Japan
2Stanford University Med. Ctr., Stanford, CA

Identification of DJ-1/Park-7 as a Determinant of Tnfα-Induced and Stroma-Dependent Apoptosis in Leukemia Using Mass Spectometry and Phosphopetide Analysis

A. Mario Q. Marcondes, MD1, Li Xiang2*, Brian P Milless3* and H. Joachim Deeg4

1Transplantation Biology, Fred Hutchinson Cancer Research and the University of Washington, Seattle, WA
2Transplantation Biology, Fred Hutchinson Cancer Research Center, Seattle, WA
3Proteomics Division, Fred Hutchinson Cancer Research Center, Seattle, WA
4Fred Hutchinson Cancer Research Center, Seattle, WA

Kpm/Lats2 of the Hippo Pathway Is Linked to Chemo-Sensitivity of Leukemic Cells

Masahiro Kawahara1*, Toshiyuki Hori1*, Kazuhisa Chonabayashi1*, Tsutomu Oka2*, Marius Sudol2* and Takashi Uchiyama1

1Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2Laboratory of Signal Transduction and Proteomic Profiling, Weis Center for Research, Danville, PA

Smad4 as a Therapeutic Target in Nup98-HoxA9-Induced Leukemia

Ronan Quere, Ph.D.1*, Goran Karlsson, Ph.D.1*, Silja Andradottir1*, Marianne Rissler1*, Karin Olsson1*, Falk Hertwig2*, Kristian Reckzeh, MSc3*, Jorg Cammenga, MD, Ph.D.1* and Stefan Karlsson, MD, Ph.D.1

1BMC A12, Lund University, Molecular Medicine and Gene Therapy, Lund, Sweden
2Lund University, BMC B10, Lund, Sweden
3Molecular Medicne and Gene Therapy, BMC A12, Lund Stem Cell Center, Lund University, Lund, Sweden

Identification of the Leukemia-Specific Domains of the CALM/AF10 Fusion Gene, a Product of the Leukemia Associated T(10;11) Translocation

Aniruddha J Deshpande1*, Natalia Arseni1*, Yihui Lin2*, Guoliang Xu2*, Wolfgang Hiddemann1, Stefan Bohlander1*, Michaela Feuring-Buske1* and Christian Buske1

1Helmholtz Centre, Munich, Munich, Germany
2Chinese Academy of Sciences, State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai, China

Regulation of the Cyclin D1 Proto-Oncogene by Cell Cycle Regulatory MicroRNAs

Anagha Borwankar1*, Alessandro Pastore1*, Aniruddha Deshpande1*, Yvonne Zimmermann1*, Christian Buske1, Wolfgang Hiddemann1 and Martin Dreyling2

1Helmholtz Centre, Munich, Munich, Germany
2Department of Internal Medicine III, University Hospital of Munich, Großhadern, Munich, Germany

EVI1 Overexpression in Pediatric Acute Myeloid Leukemia Associated with Unfavorable Subtypes

Brian V Balgobind, MD1*, Sanne Lugthart, MD2*, Iris H.I.M. Hollink, MD1*, Susan T.J.C.M. Arentsen-Peters1*, Elisabeth R van Wering3, Sibold S.N. de Graaf, MD, PhD3*, Dirk Reinhardt, MD, PhD4, Gertjan Kaspers, MD, PhD5, Jan Stary, MD, PhD6*, Jan Trka, MD, PhD7*, Martin Zimmermann, PhD8*, Ruud Delwel, PhD2, Rob Pieters, Prof.1*, Christian M Zwaan, MD, PhD9 and Marry M van den Heuvel-Eibrink, MD, PhD1*

1Department of Pediatric Hematology/Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands
2Erasmus University Medical Center, Rotterdam, Netherlands
3Dutch Childhood Oncology Group (DCOG), The Hague, Netherlands
4Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany
5VU University Medical Center, Amsterdam, Netherlands
6Dept of Pediatric Hematology and Oncology, 2nd Medical School, Charles University, University Hospital Motol, Prague, Czech Republic
7Pediatric Hematology/Oncology, Charles University, University Hospital Motol, Prague, Czech Republic
8Pediatric Hem./Onc., Medical School of Hannover, Hannover, Germany
9Department of Pediatric Hematology/Oncology, ErasmusMC Rotterdam-Sophia Children's Hospital, Rotterdam, Netherlands

A Molecular Network Comprising MicroRNA-223, E2F1 and C/Ebpα in Granulopoiesis and in Acute Myeloid Leukemia

John Anto Pulikkan1*, Viola Dengler1*, Abdul Peerzada1*, Stefan Bohlander, MD2*, Daniel G. Tenen, MD3 and Gerhard Behre1*

1Kim IV, Landeszentrum für Zell- und Gentherapie, Halle, Germany
2Medizinische Klinik III, Klinikum Grosshadern, Munich, Germany
3Harvard Inst. of Med., Boston, MA

The Role of Protein Tyrosine Phosphatase, Shp2, in FLT3-ITD-Induced Leukemogenesis

Sarah C Nabinger1*, Seiji Fukuda, M.D.2*, Reuben Kapur, PhD3 and Rebecca Chan, MD, PhD3

1Pediatrics, Indiana University School of Medicine, Indianapolis, IN
2Department of Medicine, Shimane University School of Medicine, Izumo City, Shimane 693-0021, Japan
3Indiana Univ. School of Med., Indianapolis, IN

Latexin: A Potential Tumor Suppressor

Ying Liang, Ph.D.1* and Gary Van Zant, PhD2

1Hematology/Oncology, Markey Cancer Center, Lexington, KY
2Markey Cancer Center, Lexington, KY

The PIM1 Oncogene Accelerates TCL1 Driven Lymphomagenesis in a Double-Transgenic Murine Model

Matthew I. Schrage, PhD1*, David Kim, MD2*, Jeffrey Calimlim2*, Evelena Ontiveros, MD, PhD2*, Michael A. Teitell, MD, PhD1*, Jonathan W. Said, MD1* and Sven de Vos, MD, PhD2

1Department of Pathology and Laboratory Medicine, David Geffen School of Med. at UCLA, Los Angeles, CA
2Div. of Hematology/Oncology, David Geffen School of Med. at UCLA, Los Angeles, CA

The Essential Role of Stem Cell Factor/KIT Signaling in the Proliferation and Survival of Blast Cells from Transient Leukemia in Neonates with Down Syndrome

Tsutomu Toki, PhD1, Rika Kanezaki1*, Souichi Adachi, MD, PhD2*, Hisanori Fujino, MD, PhD3*, Gang Xu1*, Tomohiko Sato1*, Kahori Suzuki1*, Hisamichi Tauchi, MD, PhD3*, Mikiya Endo, MD, PhD4* and Etsuro Ito1

1Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
2Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan
3Department of Pediatrics, Ehime University Graduate School of Medicine, Toon, Japan
4Department of Pediatrics, Iwate Medical University, Morioka, Japan

*signifies non-member of ASH